about
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularFrequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaEGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularMitotic counting in surgical pathology: sampling bias, heterogeneity and statistical uncertainty.Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome.Sputum examination for early detection of lung cancer.Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classificationEML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsA critical appraisal of prognostic and predictive factors for common lung cancers.Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria.Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?Intranodal and extranodal tumour growth in early metastasised non-small cell lung cancer: problems in histological diagnosis.Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators.Acetylcholine receptor pathway and lung cancer.The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.Neuroendocrine tumours--challenges in the diagnosis and classification of pulmonary neuroendocrine tumours.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerCytomorphometric parameters in exfoliated cells as biomarkers in head and neck cancer chemoprevention.CD44 and OTP are strong prognostic markers for pulmonary carcinoids.Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver studyA de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer.EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.A rapid, reliable method for detection of known point mutations: point-EXACCT.Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.A new brace treatment similar for adolescent scoliosis and kyphosis based on restoration of thoracolumbar lordosis. Radiological and subjective clinical results after at least one year of treatment.Number and proliferation of basal and parabasal cells in normal human airway epithelium.Glucocorticoid receptor mRNA levels in bronchial epithelial cells of patients with COPD: influence of glucocorticoids.Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells.Histological typing of lung and pleural tumours: third edition.Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial.Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer.
P50
Q26828860-8EC87931-D990-4E85-86C7-9D8E6E95CF98Q27851615-5EE3A281-12D1-464D-BF0E-AC70C9F0980BQ28303718-581CDBCD-05AF-4F60-ABF2-2AF876F2A163Q34030464-591FD035-9B17-4567-8123-ED8B8AB80613Q34159011-EBCD46C7-6FDA-4887-8AD4-052E9CE82420Q34308865-AEF8EFC7-9CC7-4D3B-BC65-F35A38A065D0Q34744444-DFFF8310-738C-460B-A365-1040BEFD2068Q35167949-632E4DA2-2861-484E-A20C-D0F658BE5C62Q35576608-B2262E13-5F21-4B37-B111-1E6B6AE2C367Q35875227-30C09F25-20BE-4439-8549-2259642B17F2Q36203525-4E11D9C0-0598-454D-83CE-3FDA0BCB5A0AQ36488342-2481C09C-6DBB-4685-95AB-9259863DD133Q36780667-2607A0C3-BEF2-4EA5-A59C-E457B36462AFQ36919313-9590EF97-1B6E-401F-9C66-E453CBC5C6C1Q37253690-31F28F63-479E-4F93-AD68-14EC5A4B33C9Q37371096-9E3DC59C-937A-4967-B830-0BEB6726CD8CQ37562739-166C8C61-3939-469C-AABA-4B1A006A4DC7Q37964331-9221AED8-1DEC-44A8-908B-B4FDAAA8DF3AQ38107755-70916E68-0DB8-4E93-8E43-975F254B76F5Q38322114-02D04D96-E78B-468D-A969-956803B2F86AQ39114274-B3CEF3C2-66C1-4671-A96F-5EF3A7C74879Q39187969-5C9B9F99-3EAB-4A6D-B3EE-85DF5F38DB5BQ39251291-5E41C732-BEC4-4FB3-AE97-E1F0998F64CCQ39498677-DA89865A-96D0-4B55-AAFC-4EFB65FD5DFBQ39765160-74DEA315-52BD-49B3-87A0-240EC0C626F0Q40129720-8EACA480-9E9B-40B3-8CFF-EDEE5CD78966Q40402101-33521DB6-71F7-4913-A139-498A2ECC3B8BQ40550067-77B15AB7-F0B1-4933-8B7F-855DDDE453B5Q41448871-A9B9BA5F-F520-4942-A4A1-B1BDD2DD9F5CQ42456416-0211F48A-6492-4BA3-8CB1-6CDC7F94E0CAQ42467241-FF3BAF8A-E6E3-46F0-8BC5-C373EC89DE9BQ42536159-6B2F5F05-C685-429A-88AE-1475679A0469Q43080931-D9DBF749-426A-4D90-B49F-11A0460900A4Q43084814-FB248385-8182-4331-8BC8-FFE2D6B5C20AQ43098017-6BE88978-0F14-4000-9DC0-0CAAC95E6D1FQ43222276-EF4F925C-150E-4F2E-A30E-12CBF9F9F6B2Q43464716-82B104F4-6153-4B79-9D81-B14EACC4F9ABQ43526022-F243C9AC-5789-4F5B-9AD2-22285BAE0FABQ43535716-FC0C4BAD-7DEC-49B0-A42F-F4EB99A853CFQ43943825-940CDCF9-EABE-4A8E-AEBD-B0DD7E0305D5
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Erik Thunnissen
@ast
Erik Thunnissen
@en
Erik Thunnissen
@es
Erik Thunnissen
@nl
Erik Thunnissen
@sl
type
label
Erik Thunnissen
@ast
Erik Thunnissen
@en
Erik Thunnissen
@es
Erik Thunnissen
@nl
Erik Thunnissen
@sl
prefLabel
Erik Thunnissen
@ast
Erik Thunnissen
@en
Erik Thunnissen
@es
Erik Thunnissen
@nl
Erik Thunnissen
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0001-5355-8508
P735
P7859
viaf-291616836